Investigation of Bisphenol A as an endocrine disruptor, total thiol, malondialdehyde, and C-reactive protein levels in chronic obstructive pulmonary disease

European Review for Medical and Pharmacological Sciences

Volumn 18, Issue 22, 2014, Pages 3477-3483

  Erden, E S ^a   Motor, S ^a   Ustun, I ^a   Demirkose, M ^a   Yuksel, R ^a   Okur, R ^a   Oktar, S ^b   Yakar, Y ^a   Sungur, S ^a   Gokce, C ^a  

^a MUSTAFA KEMAL UNIVERSITY   (Turkey)

^b MEVLANA UNIVERSITY   (Turkey)

Author keywords

Bisphenol A; C reactive protein; Chronic obstructive pulmonary disease; Malondialdehyde; Thiols

Indexed keywords

4,4' ISOPROPYLIDENEDIPHENOL; C REACTIVE PROTEIN; MALONALDEHYDE; THIOL; BENZHYDRYL COMPOUNDS; BIOLOGICAL MARKERS; BISPHENOL A; C-REACTIVE PROTEIN; ENDOCRINE DISRUPTORS; MALONDIALDEHYDE; PHENOLS; SULFHYDRYL COMPOUNDS;

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; LIPID PEROXIDATION; MALE; MIDDLE AGED; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; AGED; BLOOD; HUMANS; METABOLISM; PHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

AGED; BENZHYDRYL COMPOUNDS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; ENDOCRINE DISRUPTORS; FEMALE; HUMANS; MALE; MALONDIALDEHYDE; MIDDLE AGED; OXIDATIVE STRESS; PHENOLS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SULFHYDRYL COMPOUNDS;

EID: 84937706128     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. VESTBO J, HURD SS, AGUSTI AG, JONES PW, VOGELMEIER C, ANZUETO A, BARNES PJ, FABBRI LM, MARTINEZ FJ, NISHIMURA M, STOCKLEY RA, SIN DD, RODRIGUEZ-ROISIN R. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013; 1 87: 347-365.
2. MANNINO DM, BUIST AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet 2007; 370: 765-773.
3. CELLI BR, HALBERT RJ, NORDYKE RJ, SCHAU B. Airway obstruction in never smokers: results from the Third National Health and Nutrition Examination Survey. Am J Med 2005; 118: 1364-1372.
4. BEHRENDT CE. Mild and moderate-to-severe COPD in nonsmokers: distinct demographic profiles. Chest 2005; 128: 1239-1244.
5. BARNES PJ, CELLI BR. Systemic manifestations and comorbidities of COPD. Eur Respir J 2009; 33: 1165-1185.
6. GAN WQ, MAN SF, SENTHILSELVAN A, SIN DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-Analysis. Thorax 2004; 59: 57 4-580.
7. TANNI SE, PELEGRINO NR, ANGELELI AY, CORREA C, GODOY I. Smoking status and tumor necrosis factor-Alpha mediated systemic inflammation in COPD patients. J Inflamm (Lond) 2010; 7: 29 .
8. MACNEE W. Oxidants/antioxidants and COPD. Chest 2000; 117: 303S-317S.
9. YAO H, RAHMAN I. Current concepts on oxidative/carbonyl stress, inflammation and epigenetics in pathogen esis of chronic obstructive pulmonary disease. Toxicol Appl Pharmacol 2011; 254: 72-85.
10. ARJA C, SURAPANENI KM, RAYA P, ADIMOO LAM C, BALISETTY B, KANALA KR. Oxidative stress and antioxidant enzyme activity in South Indian male smokers with chronic obstructive pulmonary disease. Respirology 2013; 18: 1069-1075.
11. ZENG M, LI Y, JIANG Y, LU G, HUANG X, GUAN K. Local and systemic oxidative stress status in chronic obstructive pulmonary disease patients. Can Respir J 2013; 20: 35-41.
12. RAHMAN I, MACNEE W. Oxidative stress and regulation of glutathione in lung inflammation. Eur Respir J 2000; 16: 534-554.
13. PANDEY R, SINGH M, SINGHAL U, GUPTA KB, AGGARWAL SK. Oxidative/Nitrosative st ress and the pathobiology of chronic obstructive pulmonary disease. J Clin Diagn Res 2013; 7: 580-588.
14. MACNEE W. Pathogenesis of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005; 2: 258-266; discussion 290-291.
15. VANDENBERG LN, MAFFINI MV, SONNENSCHEIN C, RUBIN BS, SOTO AM. Bisphenol-A and the great divide: a review of controversies in the field of endocrine disruption. Endocrine Rev 2009; 30: 75-95.
16. CALAFAT AM, KUKLENYIK Z, REIDY JA, CAUDILL SP, EKONG J, NEEDHAM LL. Urinary concentrations of bisphenol A and 4-nonylphenol in a human reference population. Environ Health Perspect 2005; 113: 391-395.
17. MORIYAMA K, TAGAMI T, AKAMIZU T, USUI T, SAIJO M, KANAMOTO N, HATAYA Y, SHIMATSU A, KUZUYA H, NAKAO K. Thyroid hormone act ion is disrupted by bisphenol A as an antagonist. J Clin Endocrinol Metab 2002; 87: 5185-5190.
18. ERDEN ES, GENC S, MOTOR S, USTUN I, ULUTAS KT, BILGIC HK, OKTAR S, SUNGUR S, EREM C, GOKCE C. Investigation of serum bisphenol A, vitamin D, and parathyroid hormone levels in patients with obstructive sleep apnea syndrome. Endocrine 2014; 45: 311-318.
19. BINDHUMOL V, CHITRA KC, MATHUR PP. Bisphenol A induces reactive oxygen species generation in the liver of male rats. Toxicology 2003; 188: 117-124.
20. KABUTO H, HASUIKE S, MINAGAWA N, SHISHIBORI T. Effects of bisphenol A on the metabolisms of active oxygen species in mouse tissues. Environ Res 2003; 93: 31-35.
21. KABUTO H, AMAKAWA M, SHISHIBORI T. Exposure to bisphenol A during embryonic/fetal life and infancy increases oxidative injury and causes underdevelopment of the brain and testis in mice. Life Sci 2004; 74: 2931-2940.
22. YANG YJ, HONG YC, OH SY, PARK MS, KIM H, LEEM JH, HA EH. Bisphenol A exposure is associated with oxidative stress and inflammation in postmenopausal women. Environ Res 2009; 109: 797-801.
23. TANRIKULU AC, ABAKAY A, EVLIYAOGLU O, PALANCI Y. Coenzym e Q10, copper, zinc, and lipid peroxidation levels in serum of patients with chronic obstructive pulmonary disease. Biol Trace Elem Res 2011; 143: 659-667.
24. ESTERBAUER H, CHEESEMAN KH. Determination of aldehydic lipid peroxidation products: malonaldehyde and 4-hydroxynonenal. Methods Enzymol 1990; 186: 407-421.
25. HU ML. Measurement of protein thiol groups and glutathione in plasma. Methods Enzymol 1994; 233: 380-385.
26. COBELLIS L, COLACURCI N, TRABUCCO E, CARPENTIERO C, GRUMETTO L. Measurement of bisphenol A and bisp henol B levels in human blood sera from healthy and endometriotic women. Biomed Chromatogr 2009; 23: 1186-1190.
27. PINTO-PLATA VM, MULLEROVA H, TOSO JF, FEUDJO-TEPIE M, SORIANO JB, VESSEY RS, CELLI BR. C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax 2006; 61: 23-28.
28. BIZETO L, MAZZOLINI AB, RIBEIRO M, STELMACH R, CUKIER A, NUNES MP. Interrelationship between serum and sputum inflammatory mediators in chronic obstructive pulmonary disease. Brazil J Med Biol Res 2008; 41: 193-198.
29. PERERA WR, HURST JR, WILKINSON TM, SAPSFORD RJ, MULLEROVA H, DONALDSON GC, WEDZICHA JA. Inflammatory changes, recovery and recurrence at COPD exacerbation. Eur Respir J 2007; 29: 527-534.
30. DE TORRES JP, CORDOBA-LANUS E, LOPEZ-AG UILAR C, MUROS DE FUENTES M, MONTEJO DE GARCINI A, AGUIRRE-JAIME A, CELLI BR, CASANOVA C. C-reactive protein levels and clinically important predictive outcomes in stable COPD patients. Eur Respir J 2006; 27: 902-907.
31. REPINE JE, BAST A, LANKHORST I. Oxidative stress in chronic obstructive pulmonary disease. Oxidative Stress Study Group. Am J Respir Crit Care Med 1997; 156: 341-357.
32. ABBOUD RT, VIMALANATHAN S. Pathogenesis of COPD. Part I. The role of protease-Antiprotease imbalance in emphysema. Int J Tuberc Lung Dis 2008; 12: 361-367.
33. HANTA I, KOCABAS A, CANACANK ATAN N, KULECI S, SEYDAOGLU G. Oxidant-Antioxidant balance in patients with COPD. Lung 2006; 184: 51-55.
34. INONU H, DORUK S, SAHIN S, ERKORKMAZ U, CELIK D, CELIKEL S, SEYFIK LI Z. Oxidative stress levels in exhaled breath condensate associated with COPD and smoking. Respir Care 2012; 57: 413-419.
35. KARADAG F, CILDAG O, ALTINISIK M, KOZACI LD, KITER G, ALTUN C. Trace elements as a component of oxidative stress in COPD. Respirology 2004; 9: 33-37.
36. RAHMAN I, SKWARSKA E, MACNEE W. Attenuation of oxidant/antioxidant imbalance during treatment of e xacerbations of chronic obstructive pulmonary disease. Thorax 1997; 52: 565-568.
37. CORRADI M, FOLESANI G, ANDREOLI R, MANINI P, BODINI A, PIACENTINI G, CARRARO S, ZANCONATO S, BA RALDI E. Aldehydes and glutathione in exhaled breath condensate of children with asthma exacerbation. Am J Respir Crit Care Med 2003; 167: 395-399.
38. OZARAS R, TAHAN V, TURKMEN S, TALAY F, BESIRLI K, AYDIN S, UZUN H, CETINKAYA A. Changes in malondialdehyde levels in bronchoalveolar fluid and serum by the treatment of asthma with inhaled steroid and be ta2-Agonist. Respirology 2000; 5: 289-292.
39. PRAKASH M, SHETTY MS, TILAK P, ANWAR N. Total thiols: biomedical importance and their alteration in various disorders. Online J Health Allied Scs 2009; 8: 2.
40. RAHMAN I,MORRISON D,DONALDSON K,MACNEE W. Systemic oxidative stress in asthma, COPD, and smokers Am J Respir Crit Care Med 1996 154 1055-1060.
41. NADEEM A, RAJ HG, CHHABRA SK. Increased oxidative stress and altered levels of antioxidants in chronic obstructive pulmonary disease. Inflammation 2005; 29: 23-32.
42. RAUT AM, SURYAKAR AN, MHAISEKAR D. A study of oxidative stress, thiol proteins and role of vitamin E supplementation in chronic obstructive pulmonary disease (COPD). Al Ameen J Med Sci 2013; 6: 134-137.
43. CRISTOVAO C, CRISTOVAO L, NOGUEIRA F, BICHO M. Evaluation of the oxidant and antioxidant balance in the pathogenesis of chronic obstructive pulmonary disease. Rev Port Pneum ol 2013; 19: 70-75.
44. TSE HN, RAITERI L, WONG KY, YEE KS, NG LY, WAI KY, LOO CK, CHAN MH. High-dose N-Acetylcysteine in stable chronic obstructive pulmonary disease: the 1-year, dou ble-blind, randomized, placebo-controlled HIACE study. Chest 2013; 144: 106-118.
45. HANNU T, FRILANDER H, KAUPPI P, KUULIALA O, ALANKO K. IgE-mediated occupational asthma from epoxy resin. Int Arch Allergy Immunol 2009; 148: 41-44.
46. SPANIER AJ, KAHN RS, KUNSELMAN AR, HORNUNG R, XU Y, CALAFAT AM, LANPHEAR BP. Prenatal exposure to bisphenol A and child wheeze from birt h to 3 years of age. Environ Health Perspect 2012; 120: 916-920.
47. DONOHUE KM, MILLER RL, PERZANOWSKI MS, JUST AC, HOEPNER LA, ARUNAJADAI S, CANFIELD S, RESNICK D, CALAFAT AM, PERERA FP, WHYATT RM. Prenatal and postnatal bisphenol A exposure and asthma development among inner-city children. J Allergy Clinical Immunol 2013; 131: 736-742.
48. YOO SD, SHIN BS, KWACK S J, LEE BM, PARK KL, HAN SY, KIM HS. Pharmacokinetic disposition and tissue distribution of bisphenol A in rats after intravenous administration. J Toxicol Environ Health Part A 2000; 61: 131-139.
49. YAMASHITA U, SUGIURA T, YOSHIDA Y, KURODA E. Effect of endocrine disrupters on macrophage functions in vitro. J UOEH 2005; 27: 1-10.
50. TEPPALA S, MADHAVAN S, SHANKAR A. Bisphenol A and metabolic syndrome: results from NHANES. Int J Endocrinol 2012; 2012: 598180.
51. OZBEK M, CAKIR E, OZKAYA E, COLAK N, CAKAL E, YAZICIOGLU YA, MENTESE A, TURAN I, DELIBASI T. Oxidative stress markers in metabolic syndrome. Turk Jem 2011; 15: 57-61.
52. HOLLOWAY RA, DONNELLY LE. Immunopathogenesis of chronic obstructive pulmonary disease. Curr Opin Pulm Med 2013; 19: 95-102.
53. CHITRA KC, LATCHOUMYCANDANE C, MATHUR PP. Induction of oxidative stress by bisphenol A in the epididymal sperm of rats. Toxicology 2003; 185: 119-127.
54. SANGAI NP, VERMA RJ, TRIVEDI MH. Testing the efficacy of quercetin in mitigating bisphenol A toxicity in liver and kidney of mice. Toxicol Ind Health 2012; 30: 581-597.
55. YI B, KASAI H, LEE HS, KANG Y, PARK JY, YANG M. Inhibition by wheat sprout (Triticum aestivum) juice of bisphenol A-induced oxidative stress in young women. M utation Res 2011; 724: 64-68.